Acquisition leverage Veristat has recently acquired Instat, expanding its biometric and statistical services footprint. This creates an opportunity to engage as Veristat integrates Instat capabilities for end-to-end clinical research solutions, potentially offering bundled services to sponsors seeking single-vendor flexibility.

Statistical leadership Instat specializes in statistics, data management and medical writing across all clinical phases. Target opportunities include sponsors needing robust statistical design, protocol development and regulatory submission support, positioning as a turnkey data management and biostatistics partner.

Data management focus With expertise in EDC database creation and data management, there is potential to upsell enhanced data capture, cleaning and analytics solutions, appealing to sponsors planning complex trials or expanding biotechnology portfolios.

SMB to mid-market Current employee range and revenue indicate mid-market focus. Prospect strategy can target mid-sized biotech and specialty pharma firms seeking cost-effective, scalable CRO services with high-touch scientific expertise.

Strategic partnerships Historical collaborations with coaching, scouting and performance analytics players show a pattern of partnerships. Leverage this network to propose integrated offerings for trial planning, data analytics, and regulatory submissions to enhance sponsor outcomes.